Products Affected - Description

• • Nipent powder for solution for injection, Pfizer, 10 mg, vial, 1 count, NDC 00409-0801-01

Reason for the Shortage

• • Pfizer has Nipent on shortage due to manufacturing delays.

Available Products

• • There are no presentations available

• • Pfizer has Nipent 10 mg vials on back order and the company cannot estimate a release date. Product is not expected to be available in 2027.

• • Consider evaluating the health-care system's total supply of pentostatin before beginning patients on chemotherapy regimens containing pentostatin. If adequate supplies are not available, select an alternative regimen.
  • The choice of an alternative agent must be patient-specific and based on renal function, liver function, and the neoplasm type and location. No single agent can be substituted for pentostatin.
  • Consult a Hematology/Oncology specialist for patient- and neoplasm-specific recommendations.
  • Refer to the ASHP Infographics on Drug Product Shortages for more guidance on developing a multidisciplinary plan when the supply must be allocated. https://www.ashp.org/-/media/assets/drug-shortages/docs/ASHP-drug-shortages-infographic.pdf?rev=8c909ada5cfb4f05a28d5452eb57dd16
  • Refer to national guidelines such as those from the National Comprehensive Cancer Network (www.nccn.org) or American Society of Clinical Oncology (http://www.asco.org/) for additional information regarding therapeutic use.